RTP Mobile Logo
PARP Inhibition in Four Common Cancers: Biology, Clinical Research Database and Therapeutic Strategy
Released June 2019

Faculty presentations from a CME symposium held at the 2019 AACR Annual Meeting. Featuring perspectives from Drs Emmanuel S Antonarakis, Kathleen Moore, Michael J Pishvaian and Melinda Telli. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

    OVERVIEW OF ACTIVITY
    Over the past 2 decades, the oncology community has witnessed a significant transformation in the way clinicians think about and approach the diagnosis and treatment of a variety of solid tumors and hematologic cancers. During this time, a shift has occurred from a “one-size-fits-all” approach to one in which therapeutic decision-making is routinely informed by the presence of molecular alterations and/or relevant biomarkers. Given that one cancer may share a number of biologic similarities with another and that abnormalities found in one disease may be present in others, it is not surprising that attempts are underway to apply knowledge and therapeutic understanding across multiple diseases. This rational approach to clinical research has now yielded a growing body of evidence illustrating that a single targeted therapy can provide demonstrable benefit for patients with the same identified genetic abnormality regardless of the type of cancer. One of the most compelling recent examples of this phenomenon has been the documentation of the efficacy of PARP inhibitors in various solid tumors.

    This CME program developed from the proceedings of a CME symposium held during the 2019 AACR Annual Meeting features video slide presentations given by leading investigators in ovarian, breast, pancreatic and prostate cancer regarding the underlying biology and current research database in support of the use of PARP inhibitors as a therapeutic strategy. By providing information on important developments, this CME activity will assist medical oncologists and other healthcare professionals to address existing management uncertainties and determine the clinical role of PARP inhibition in these diseases.

    LEARNING OBJECTIVES

    • Consider the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeutic options.
    • Appraise available guideline recommendations and evidence-based modalities for genetic testing in ovarian and breast cancer, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
    • Describe the rationale for testing patients with metastatic prostate cancer or pancreatic adenocarcinoma for mutations in homology-directed DNA repair predisposition genes, and advise individuals found to harbor these genetic abnormalities about participation in clinical trials evaluating PARP inhibitors.
    • Appreciate available clinical trial data with FDA-approved PARP inhibitors for patients with ovarian cancer to safely integrate these agents into routine clinical care.
    • Evaluate the recent FDA approvals of olaparib and talazoparib for patients with HER2-negative metastatic breast cancer harboring a germline BRCA mutation, and discern how these agents can be appropriately and safely integrated into routine clinical practice.
    • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AACR19/PARP/Video/CME. The corresponding audio program is available at ResearchToPractice.com/AACR19/PARP.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Emmanuel S Antonarakis, MD
    Associate Professor of Oncology and Urology
    Johns Hopkins University
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee and Consulting Agreements: Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Dendreon Pharmaceuticals Inc, ESSA Pharma Inc, Janssen Biotech Inc, Medivation Inc, a Pfizer Company, Merck, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Dendreon Pharmaceuticals Inc, Genentech, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Sanofi Genzyme, Tokai Pharmaceuticals Inc; Other Remunerated Activities: Co-inventor of a biomarker licensed to QIAGEN.

    Kathleen Moore, MD
    Jim and Christy Everest Endowed Chair in Cancer Research
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, ImmunoGen Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Samumed, Tesaro, VBL Therapeutics; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics, Roche Laboratories Inc.

    Michael J Pishvaian, MD, PhD
    Phase I Program Director
    Medical Director of the CRMO
    Associate Professor
    Lombardi Comprehensive Cancer Center
    Washington, DC

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Celgene Corporation, Merrimack Pharmaceuticals Inc, Perthera Inc, RenovoRx; Contracted Research: ARMO Biosciences, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Curegenix Inc, FibroGen, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Halozyme Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, MedImmune Inc, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Tesaro; Ownership Interest: Perthera Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Perthera Inc, Sirtex Medical Ltd; Speakers Bureau: Sirtex Medical Ltd.

    Melinda Telli, MD
    Associate Professor of Medicine
    Stanford University School of Medicine
    Leader, Breast Oncology Clinical Research Group
    Stanford Cancer Institute
    Stanford, California

    Advisory Committee: Aduro Biotech, Celgene Corporation, Genentech, Immunomedics Inc, Merck; Consulting Agreement: Pfizer Inc; Contracted Research: Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro; Data and Safety Monitoring Board: G1 Therapeutics.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: June 2019
    Expiration date: June 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):